mercilon 28
organon (new zealand) limited - desogestrel 150ug; ; ethinylestradiol 20ug; - tablet - active: desogestrel 150ug ethinylestradiol 20ug excipient: colloidal silicon dioxide dl-alpha tocopherol lactose monohydrate magnesium stearate potato starch povidone stearic acid lactose monohydrate magnesium stearate potato starch - oral contraception.
mercilon 21
merck sharp & dohme (new zealand) limited - desogestrel 150ug; ; ethinylestradiol 20ug; - tablet - active: desogestrel 150ug ethinylestradiol 20ug excipient: colloidal silicon dioxide dl-alpha tocopherol lactose monohydrate magnesium stearate potato starch povidone stearic acid
desogestrel and ethinyl estradiol- desogestrel and ethinyl estradiol
mylan pharmaceuticals inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - desogestrel and ethinyl estradiol tablets usp, 0.15 mg/0.03 mg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typical use an
desogestrel and ethinyl estradiol- desogestrel and ethinyl estradiol kit
mayne pharma inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets, usp are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. emergency contraceptive pills: treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregna
desogestrel 75 microgram film-coated tablets
laboratorios león farma, s.a. - desogestrel - film-coated tablet - 75 mg - hormonal contraceptives for systemic use - oral contraception
desogestrel rowex 75 microgram film-coated tablets
rowex ltd - desogestrel - film-coated tablet - 75 microgram(s) - progestogens; desogestrel - : hormonal contraceptives for systemic use - contraception
desogestrel and ethinyl estradiol
northstar rx llc - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg
desogestrel besins 75 µg film-coat. tabl.
besins healthcare sa-nv - desogestrel 0,075 mg - film-coated tablet - 75 µg - desogestrel 75 µg - desogestrel
desogestrel and ethinyl estradiol kit
naari pte limited - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets usp 0.15 mg/0.03 mg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. desogestrel and ethinyl estradiol tablets 0.15 mg/0.03 mg has not been studied for and is not indicated for
desogestrel and ethinyl estradiol and ethinyl estradiol kit
naari pte. limited - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel and ethinyl estradiol tablets, usp and ethinyl estradiol tablets, usp is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year a method (1) typical use b (2) perfect use c (3) (4) chance d 85 85 spermicides e 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal f 2 post-ovulation 1 withdrawal 19 4 cap g parous wome